Literature DB >> 10952623

Anti-toxoplasma activities of antiretroviral drugs and interactions with pyrimethamine and sulfadiazine in vitro.

F Derouin1, M Santillana-Hayat.   

Abstract

The anti-Toxoplasma activities of nine antiretroviral drugs were examined in vitro. Nucleoside analogs had no effect on parasite growth, whereas ritonavir and nelfinavir were inhibitory for Toxoplasma, with 50% inhibitory concentrations of 5.4 and 4.0 microg/ml, respectively. None of the antiviral drugs affected the anti-Toxoplasma activity of pyrimethamine or sulfadiazine.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10952623      PMCID： PMC90113          DOI： 10.1128/AAC.44.9.2575-2577.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  In vitro activity of human immunodeficiency virus protease inhibitors against Pneumocystis carinii.

Authors:  C Atzori; E Angeli; A Mainini; F Agostoni; V Micheli; A Cargnel
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

2.  1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with Human Immunodeficiency Virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. Infectious Diseases Society of American.

Authors: 
Journal:  Ann Intern Med       Date:  1999-12-07       Impact factor: 25.391

Review 3.  Proteases of protozoan parasites.

Authors:  P J Rosenthal
Journal:  Adv Parasitol       Date:  1999       Impact factor: 3.870

Review 4.  HIV-protease inhibitors.

Authors:  C Flexner
Journal:  N Engl J Med       Date:  1998-04-30       Impact factor: 91.245

5.  The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring.

Authors:  G Gatti; A Di Biagio; R Casazza; C De Pascalis; M Bassetti; M Cruciani; S Vella; D Bassetti
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

6.  Zidovudine antagonizes the action of pyrimethamine in experimental infection with Toxoplasma gondii.

Authors:  D M Israelski; C Tom; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 7.  Nelfinavir mesylate: a protease inhibitor.

Authors:  V B Pai; M C Nahata
Journal:  Ann Pharmacother       Date:  1999-03       Impact factor: 3.154

8.  In vitro effects of folate inhibitors on Toxoplasma gondii.

Authors:  F Derouin; C Chastang
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

9.  Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients.

Authors:  C Merry; M G Barry; F Mulcahy; M Ryan; J Heavey; J F Tjia; S E Gibbons; A M Breckenridge; D J Back
Journal:  AIDS       Date:  1997-03-15       Impact factor: 4.177

Review 10.  Toxoplasmic encephalitis in AIDS.

Authors:  B J Luft; J S Remington
Journal:  Clin Infect Dis       Date:  1992-08       Impact factor: 9.079
View more
  11 in total

1.  Image-based high-throughput drug screening targeting the intracellular stage of Trypanosoma cruzi, the agent of Chagas' disease.

Authors:  Juan C Engel; Kenny K H Ang; Steven Chen; Michelle R Arkin; James H McKerrow; Patricia S Doyle
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

2.  Repurposing the open access malaria box to discover potent inhibitors of Toxoplasma gondii and Entamoeba histolytica.

Authors:  Fabrice F Boyom; Patrick V T Fokou; Lauve R Y Tchokouaha; Thomas Spangenberg; Alvine N Mfopa; Ruffin M T Kouipou; Cedric J Mbouna; Valerie F Donkeng Donfack; Paul H A Zollo
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

Review 3.  Importance of nonenteric protozoan infections in immunocompromised people.

Authors:  J L N Barratt; J Harkness; D Marriott; J T Ellis; D Stark
Journal:  Clin Microbiol Rev       Date:  2010-10       Impact factor: 26.132

4.  Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assay.

Authors:  Jean Menotti; Maud Santillana-Hayat; Bruno Cassinat; Claudine Sarfati; Francis Derouin; Jean-Michel Molina
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  Toxoplasma gondii antibody profile in HIV-infected pregnant women and the risk of congenital toxoplasmosis.

Authors:  E G Lago; G S Conrado; C S Piccoli; R L Carvalho; A L Bender
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-10-15       Impact factor: 3.267

6.  Population pharmacokinetics of pyrimethamine and sulfadoxine in children treated for congenital toxoplasmosis.

Authors:  Stéphane Corvaisier; Bruno Charpiat; Cyril Mounier; Martine Wallon; Gilles Leboucher; Mounzer Al Kurdi; Jean-François Chaulet; François Peyron
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

7.  Great efficacy of sulfachloropyrazine-sodium against acute murine toxoplasmosis.

Authors:  Yan-Bo Zeng; Shun-Hai Zhu; Hui Dong; Hong-Yu Han; Lian-Lian Jiang; Quan Wang; Jun Cheng; Qi-Ping Zhao; Wei-Jiao Ma; Bing Huang
Journal:  Asian Pac J Trop Biomed       Date:  2012-01

8.  HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.

Authors:  Yenisey Alfonso; Lianet Monzote
Journal:  Open Med Chem J       Date:  2011-03-09

9.  Crystal structure of the retroviral protease-like domain of a protozoal DNA damage-inducible 1 protein.

Authors:  Sushant Kumar; Kaza Suguna
Journal:  FEBS Open Bio       Date:  2018-08-03       Impact factor: 2.693

10.  In vitro effectivity of three approved drugs and their synergistic interaction against Leishmania infantum.

Authors:  Iman Fathy Abou-El-Naga; Rasha Fadly Mady; Nermine Mogahed Fawzy Hussien Mogahed
Journal:  Biomedica       Date:  2020-05-01       Impact factor: 0.935
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.